Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
News-Medical.Net on MSN
Non-coding RNA mutations unveiled as new cause of retinitis pigmentosa
Retinitis pigmentosa (RP) is a genetic eye disorder affecting around one in 5,000 people worldwide. It typically begins with ...
News-Medical.Net on MSN
RNA gene mutations identified as cause of inherited blindness
Researchers from Radboud university medical center and University of Basel have discovered new genetic causes of inherited ...
Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do ...
In an investigation to find out what sparked life on Earth, researchers have discovered that RNA formed through surprisingly ...
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
A giant impact on the early Earth could have brought the building blocks of RNA to our planet, which new research suggests ...
AZoLifeSciences on MSN
Synthetic RNA platform converts viral replication into detectable cellular signals
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...
Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback